Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BECTON, DICKINSON AND COMPANY

(BDX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Becton Dickinson and : BD Launches Plunger Stopper in Partnership with Aptar Pharma to Enhance Biologic Drug Delivery

10/13/2021 | 10:02am EST

New product is intended to support biologic drugs with high viscosity formulations*, complex design space requirements and support the delivery of medications for chronic diseases

FRANKLIN LAKES, N.J. (October 13, 2021) - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD SCF™ PremiumCoat® Plunger Stopper in partnership with Aptar Pharma, a global leader in drug delivery solutions and services.

BD SCF™ PremiumCoat®† is a syringe plunger stopper designed to support the injection of biologics into subcutaneous tissue with a 1mlL pre-filled syringe. The design incorporates Aptar Pharma's state-of-the-art rubber formulation and proven film technology§ intended to limit drug component interactions and ensure drug integrity. BD SCF™ PremiumCoat®† is designed to deliver improved functional performance, such as reduced glide force¶,#,^ and glide force variability¶,#,^ in a combination product.

"Biologics represent a critical and fast-growing segment of the drug market in the fight against serious diseases," said Eric Borin, worldwide president of BD Medical-Pharmaceutical Systems. "Enhanced biologic combination products are needed to ensure that patients and their caregivers can administer these drugs from the comfort of their homes. This partnership with Aptar Pharma will help deliver on that need."

The BD SCF™ PremiumCoat®† Plunger Stopper addresses the need of pharmaceutical companies to de-risk drug development and support time to market while improving operational efficiencies and reducing stopper-related quality issues1. The quality of this stopper is verified, in part, using BD Visioguard™ 100 percent camera inspection. This inspection serves to ensure that BD SCF™ PremiumCoat®† 1mlL Plunger Stoppers meet customer specifications and help reduce the risk of foreign matter contaminationμ,2.

"The launch of BD SCF™ PremiumCoat®† Plunger Stopper, merging BD and Aptar Pharma's expertise, brings a new generation of coated plunger stopper solutions to the market to support the protection of sensitive drugs by reducing the quantity and species of probable leachables," said Gabriel Zenker, President, Aptar Pharma Injectables. "In partnering with BD, we look forward to furthering our support of biotech companies in their efforts to provide safe and easy-to-use drug delivery systems, while we continue to invest in new technologies to address the evolving needs of market."

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc. (NYSE: ATR), a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar's innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world's leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

Contacts:
Media:Investors:

Trey Hollern Nadia Goncalves
Director, Public Relations Senior Director, Investor Relations
862.284.8629 201.847.5934
trey.hollern@bd.comnadia.goncalves@bd.com

Disclaimer

BD - Becton, Dickinson and Company published this content on 13 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 October 2021 14:01:05 UTC.


ę Publicnow 2021
All news about BECTON, DICKINSON AND COMPANY
12/02U.S. OMICRON PLAN : boosters, free at-home tests, tighter travel rules
RE
12/02Becton, Dickinson and Co. Buys Venclose for Undisclosed Sum
MT
12/02BD Acquires Venclose, Inc. To Extend Treatment Innovations In Chronic Venous Disease
PR
12/02Becton, Dickinson and Company acquired Venclose, Inc.
CI
12/01BD Issues 2021 Global Inclusion, Diversity and Equity Report
PR
11/30Becton, Dickinson Says Rapid Antigen, PCR Tests Capable of Detecting Omicron Variant
MT
11/30BD Statement on Testing for the COVID-19 Omicron Variant of Concern
PR
11/30BD Names Dr. Joseph M. Smith as Chief Scientific Officer Digital Health Pioneer to Focu..
AQ
11/29Becton, Dickinson and Company Appoints Joseph M. Smith as Senior Vice President, Chief ..
CI
11/24BECTON DICKINSON & CO Management's Discussion and Analysis of Financial Condition and ..
AQ
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Financials (USD)
Sales 2022 19 416 M - -
Net income 2022 2 337 M - -
Net Debt 2022 13 262 M - -
P/E ratio 2022 31,0x
Yield 2022 1,55%
Capitalization 69 336 M 69 336 M -
EV / Sales 2022 4,25x
EV / Sales 2023 3,95x
Nbr of Employees 75 000
Free-Float 77,5%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | BDX | US0758871091 | MarketScreener
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 244,12 $
Average target price 273,38 $
Spread / Average Target 12,0%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Chris DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Jerry Flasz Chief Information Officer & EVP-Global Services
Elizabeth McCombs Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY-3.42%69 336
ABBOTT LABORATORIES18.98%230 355
MEDTRONIC PLC-8.77%143 693
HOYA CORPORATION28.35%59 756
DEXCOM, INC.40.51%50 350
SARTORIUS STEDIM BIOTECH65.52%49 924